

UNITED STATES DEPARTMENT OF COMMERCE Patent and Trademark Office

Address: COMMISSIONER OF PATENTS AND TRADEMARKS Washington, D.C. 20231

SERIAL NUMBER	FILING DATE	FIRST NAMED APPLICANT		ATTORNEY DOCKET NO.
06/344,350	01/29/82	COLBRY	И	

TSTEPHEN I. MILLER 201 TABOR ROAD MORRIS PLAINS, NJ 07950

EXAMINER						
TURNIPSEED # J						
ART UNIT	PAPER NUMBER					
122						
DATE MAILED:	08/25/82					

This is a communication from the examiner in charge of your application.

COMMISSIONER OF PATENTS AND TRADEMARKS

This application has been examined.		rte.	
		4 1'n	is action is made final.
A shortened statutory period for response to this action is set to expire month(s),	d	lays from the dat	e of this letter.
Failure to respond within the period for response will cause the application to become abandone	d. 35 U	J.S.C. 133	
Part I THE FOLLOWING ATTACHMENT(S) ARE PART OF THIS ACTION:			
1. Notice of References Cited by Examiner, PTO-892 2. Notice of Info	rmal Patent	Drawing, PTO-9	48
3. Notice of References Cited by Applicant, PTO-1449 4. Notice of Info	ormal Patent	Application, Fo	rm PTO-152
5.			
Part II SUMMARY OF ACTION			
1. X Claims 1-8		are pending	in the application.
Of the above, claims		are withdrav	vn from consideration.
2. Claims		have been ca	ncelled.
3. Claims		are allowed.	
4. X Claims		are rejected.	
5. Claims		are objected	to.
6. Claims	_ are subject	t to restriction or	election requirement.
7. The formal drawings filed on	are acceptable.		
8. The drawing correction request filed on	_ has been	approved.	disapproved.
9. Acknowledgment is made of the claim for priority under 35 U.S.C. 119. The certified	copy has		
been received. Inot been received. been filed in parent application, s			
			,
filed on	•		
10. Since this application appears to be in condition for allowance except for formal matter cordance with the practice under Ex parte Quayle, 1935 C.D. 11; 453 O.G. 213.	ers, prosecut	tion as to the me	rits is closed in ac-
11. Other			

Serial No. 344350 Art Unit 122

The references cited but copy of which is not supplied was cited and supplied in the parent file. The additional references are cited to show the state of the art.

The requirement is made for the insertion of the $\mathcal{S}^{\mathcal{K}}$ status of the application inserted at page 1 of the specification.

The disclosure is objected to as failing to comply with the best mode requirement as required by the first paragraph of 35 U.S.C. 112. This paragraph of the statute, requires that the specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same, and shall set forth the best mode contemplated by the inventor of carrying out his invention.

There is no adequate showing that the compounds of the instant claims can be used in treating tumors and psoriasis as is recited in the "Abstract of the Disclosure and at page 9, forth paragraph to page 10, the last two paragraphs thereon. Note MPEP 608.01 (p). Applicant is required to either cancel the references to treating tumors and psorias from the specification or to present some evidence, either direct or indirect

014

Serial No.344350
Art Unit 122

-3-

to support the use of treating mammals, especially humans, with the compounds of the instant claims.

Claims 1-9 are rejected under 35 U.S.C. 112, first paragraph, for the reasons set forth in the preceding paragraph(s).

Claims 1-8 are rejected under 35 U.S.C. 103 as being unpatentable over Elslager, et al. Although, the invention is not identically disclosed or described as set forth in section 102 of Title 35 U.S.C., the differences between the subject matter sought to be patented and the prior art are such that the subject matter as a whole would have been obvious at the time the invention was made to a person having ordinary skill in the art to which said subject matter pertains.

Elslager, et al discloses the free base of the instantly claimed compounds and teach at page 2, col.2 that salts thereof may be formed with organic acids. Although applicant teach that the compounds of the instant claims are more soluble in water than other salts of the free base, this alone is not deemed to be sufficient to render the instantly claimed compounds patentable over the free base, especially in view of the common utility and further since it is well known in the art that drugs are commonly used in the form of their salts, as is taught by Berge, et al and further since it is well known that some salts have greater

Serial No. 344350 Art Unit 122

Solubility than others as is taught by McElvain. Therefore, the compounds of the instant claims would be readily suggested to one of ordinary skill in the art, especially in the absence of some unexpected property or results.

unpatentable over Elslager, et al. Although, the invention is not identically disclosed or described as set forth in section 102 of Title 35 U.S.C., the differences between the subject matter sought to be patented and the prior art are such that the subject matter as a whole would have been obvious at the time the invention was made to a person having ordinary skill in the art to which said subject matter pertains.

Elslager, et al disclose the process of the instant claim employing analogous reactants. The instantly claimed process would be readily suggested to one of skill in the art.

Claims 1-9 are rejected.

This application is a continuation application of an earlier application. Further, all claims are: (a) drawn to the same invention claimed in the earlier application, and (b) would have been properly finally rejected on the grounds or art of record in the next Office action if they had been entered in the earlier application.

Accordingly, THIS OFFICE ACTION IS PROPERLY MADE

FINAL even though it is a first action in this case. See MPEP 706.07(b).

Turnipseed:cvm

A/C 703

557-3032

8/19/82

a G. Daus Supervisory Patent Examilia. Art Unit 122

.